These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20817265)

  • 1. Risedronate metal complexes potentially active against Chagas disease.
    Demoro B; Caruso F; Rossi M; Benítez D; Gonzalez M; Cerecetto H; Parajón-Costa B; Castiglioni J; Galizzi M; Docampo R; Otero L; Gambino D
    J Inorg Biochem; 2010 Dec; 104(12):1252-8. PubMed ID: 20817265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi.
    Garzoni LR; Caldera A; Meirelles Mde N; de Castro SL; Docampo R; Meints GA; Oldfield E; Urbina JA
    Int J Antimicrob Agents; 2004 Mar; 23(3):273-85. PubMed ID: 15164969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.
    Demoro B; Caruso F; Rossi M; Benítez D; González M; Cerecetto H; Galizzi M; Malayil L; Docampo R; Faccio R; Mombrú AW; Gambino D; Otero L
    Dalton Trans; 2012 Jun; 41(21):6468-76. PubMed ID: 22344249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.
    Garzoni LR; Waghabi MC; Baptista MM; de Castro SL; Meirelles Mde N; Britto CC; Docampo R; Oldfield E; Urbina JA
    Int J Antimicrob Agents; 2004 Mar; 23(3):286-90. PubMed ID: 15164970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate in the treatment of Murine Chagas' disease.
    Bouzahzah B; Jelicks LA; Morris SA; Weiss LM; Tanowitz HB
    Parasitol Res; 2005 Jun; 96(3):184-7. PubMed ID: 15844009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antiparasital activity against Trypanosoma cruzi of three novel 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one-based complexes.
    Caballero AB; Marín C; Rodríguez-Diéguez A; Ramírez-Macías I; Barea E; Sánchez-Moreno M; Salas JM
    J Inorg Biochem; 2011 Jun; 105(6):770-6. PubMed ID: 21497152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising fluconazole based zinc(II) and copper(II) coordination polymers against Chagas disease.
    de Azevedo-França JA; Barrias E; Franco CHJ; Villarreal W; Vieira EG; Ferreira AMDC; de Souza W; Navarro M
    J Inorg Biochem; 2022 Aug; 233():111834. PubMed ID: 35500350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibandronate metal complexes: solution behavior and antiparasitic activity.
    Demoro B; Rostán S; Moncada M; Li ZH; Docampo R; Olea Azar C; Maya JD; Torres J; Gambino D; Otero L
    J Biol Inorg Chem; 2018 Mar; 23(2):303-312. PubMed ID: 29349663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterobimetallic nickel(II) and palladium(II) complexes derived from S-benzyl-N- (ferrocenyl)methylenedithiocarbazate: Trypanocidal activity and interaction with Trypanosoma cruzi Old Yellow Enzyme (TcOYE).
    Carneiro ZA; Lima JC; Lopes CD; Gaspari APS; de Albuquerque S; Dinelli LR; Veloso-Silva LLW; Paganelli MO; Libardi SH; Oliveira CG; Deflon VM; Oliveira RJ; Borges JC; Maia PIS
    Eur J Med Chem; 2019 Oct; 180():213-223. PubMed ID: 31306908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures.
    Gossman WL; Wilson SR; Oldfield E
    Acta Crystallogr C; 2003 Feb; 59(Pt 2):m33-6. PubMed ID: 12574640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc 1,2,4-triazolo[1,5-a]pyrimidine Complexes: Synthesis, Structural Characterization and their Effect Against Chagas Disease.
    Méndez-Arriaga JM; Rubio-Mirallas E; Quirós M; Sánchez-Moreno M
    Med Chem; 2022; 18(4):444-451. PubMed ID: 34387166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new dinuclear Fe(III) coordination compounds with
    Moreira FF; Portes JA; Barros Azeredo NF; Fernandes C; Horn A; Santiago CP; Segat BB; Caramori GF; Madureira LMP; Candela DRS; Marques MM; Lamounier Camargos Resende JA; de Souza W; DaMatta RA; Seabra SH
    Dalton Trans; 2021 Sep; 50(35):12242-12264. PubMed ID: 34519725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity on Trypanosoma cruzi, erythrocytes lysis and biologically relevant physicochemical properties of Pd(II) and Pt(II) complexes of thiosemicarbazones derived from 1-indanones.
    Santos D; Parajón-Costa B; Rossi M; Caruso F; Benítez D; Varela J; Cerecetto H; González M; Gómez N; Caputto ME; Moglioni AG; Moltrasio GY; Finkielsztein LM; Gambino D
    J Inorg Biochem; 2012 Dec; 117():270-6. PubMed ID: 23063173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallization and preliminary neutron diffraction experiment of human farnesyl pyrophosphate synthase complexed with risedronate.
    Yokoyama T; Ostermann A; Mizuguchi M; Niimura N; Schrader TE; Tanaka I
    Acta Crystallogr F Struct Biol Commun; 2014 Apr; 70(Pt 4):470-2. PubMed ID: 24699741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
    Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
    Szajnman SH; García Liñares GE; Li ZH; Jiang C; Galizzi M; Bontempi EJ; Ferella M; Moreno SN; Docampo R; Rodriguez JB
    Bioorg Med Chem; 2008 Mar; 16(6):3283-90. PubMed ID: 18096393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New achievements on biological aspects of copper complexes Casiopeínas®: interaction with DNA and proteins and anti-Trypanosoma cruzi activity.
    Becco L; Rodríguez A; Bravo ME; Prieto MJ; Ruiz-Azuara L; Garat B; Moreno V; Gambino D
    J Inorg Biochem; 2012 Apr; 109():49-56. PubMed ID: 22377716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi.
    Navarro M; Cisneros-Fajardo EJ; Lehmann T; Sánchez-Delgado RA; Atencio R; Silva P; Lira R; Urbina JA
    Inorg Chem; 2001 Dec; 40(27):6879-84. PubMed ID: 11754267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heteroleptic oxidovanadium(IV) complexes of 2-hydroxynaphtylaldimine and polypyridyl ligands against Trypanosoma cruzi and prostate cancer cells.
    Scalese G; Mosquillo MF; Rostán S; Castiglioni J; Alho I; Pérez L; Correia I; Marques F; Costa Pessoa J; Gambino D
    J Inorg Biochem; 2017 Oct; 175():154-166. PubMed ID: 28755573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
    Gabelli SB; McLellan JS; Montalvetti A; Oldfield E; Docampo R; Amzel LM
    Proteins; 2006 Jan; 62(1):80-8. PubMed ID: 16288456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.